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Background: Autosomal dominant polycystic kidney disease (ADPKD) causes progressive renal damage and is a
leading cause of end-stage renal failure. With emerging therapies it is important to devise a method for early
detection. We aimed to identify factors from routine clinical data which can be used to distinguish people with a
high likelihood of having ADPKD in a primary health care setting.
Method: A cross-sectional study was undertaken using data from the Quality Intervention in Chronic Kidney Disease
trial extracted from 127 primary care practices in England. The health records of 255 people with ADPKD were
compared to the general population. Logistic regression was used to identify clinical features which distinguish
ADPKD. These clinical features were used to stratify individual risk using a risk score tool.
Results: Renal impairment, proteinuria, haematuria, a diastolic blood pressure over 90 mmHg and multiple
antihypertensive medications were more common in ADPKD than the general population and were used to build a
regression model (area under the receiver operating characteristic curve; 0.79). Age, gender, haemoglobin and
urinary tract infections were not associated with ADPKD. A risk score (range −3 to +10) of ≥0 gave a sensitivity of
70.2% and specificity 74.9% of for detection.
Conclusions: Stratification of ADPKD likelihood from routine data may be possible. This approach could be a
valuable component of future screening programs although further longitudinal analyses are needed.
Keywords: Autosomal dominant polycystic kidney disease, Screening, Early detection, Primary care recordsBackground
Autosomal dominant polycystic kidney disease (ADPKD)
is a major cause of end-stage renal disease (ESRD) and
may result in the need for renal replacement therapy [1].
ADPKD is the most common form of polycystic kidney
disease and one of the most common genetic diseases
with a reported prevalence of around 1 in 400 to 1000
and accounts for 7-10% of patients with end-stage renal
disease (ESRD) [2-5]. It is genetically heterogeneous with
80-85% of cases due to mutations in PKD1 with the
remainder due to mutations in PKD2. Mutations in
PKD2 predict a milder phenotype with ESRD occurring* Correspondence: andy@mcgov.co.uk
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article, unless otherwise stated.at a median age of 79 years compared to 58 years in
individuals with a PKD1 mutation [6].
Expansion of renal cysts causes distortion and com-
pression of normal renal tissues, intrarenal ischaemia,
hyper-activation of the renin-angiotensin-aldosterone
system (RAAS) and the development of sustained hyper-
tension [7,8]. Hypertension results in cardiovascular
disease, the leading cause of death in ADPKD [9], renal
function decline [10], and may also further accelerate
cyst growth [11]. Treatment of hypertension with
angiotensin-converting enzyme inhibitors (ACEIs) has
been hypothesised to prevent or delay these effects.
Longitudinal studies in people with ADPKD demon-
strate ACEI use is associated with slower progression of
renal disease and increased duration of survival [12,13]
although the results of the HALT study on standardtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Read codes used to define autosomal dominant
polycystic kidney disease
Clinical
code
Code term
Read codes: 5-byte version 2
PD11. Polycystic kidney disease
PD111 Polycystic kidneys, adult type
PD11z Polycystic kidney disease NOS
Read codes: version 3
PD11. Polycystic kidney disease
PD111 ADPKD - Autosomal dominant polycystic kidney disease
X785m Cystic kidney disease NEC
X785n Adult type polycystic kidney disease type 1
X785o Adult type polycystic kidney disease type II
X785p Autosomal dominant polycystic kidney disease in
childhood
XE1LN Polycystic kidney disease NOS
XM19L Polycystic kidneys, adult type (dominant) associated
with renal failure
NOS = not otherwise specified, NEC = not elsewhere classified.
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blockade on disease progression are awaited [14].
Studies using retrospective data from large registries
have so far not shown any long term benefit of standard
care for chronic kidney disease (CKD) on ADPKD pro-
gression [15]. However, novel therapies targeting cAMP
production in the kidney have shown promise in ADPKD
treatment. Trials of somatostatin analogues demonstrate a
reduced rate of increase in total kidney volume but no
effect on renal function has yet been identified [16-19].
A 3-year randomised controlled trial demonstrated the
vasopressin receptor antagonist tolvaptan slows both
cyst growth and decline in renal function compared
with placebo [20] although additional safety and efficacy
data have been requested before licensing [21]. Many
additional drug therapies are also under investigation
[22]. With potentially effective therapies now on the
horizon it is important to devise a method for early
detection of ADPKD in addition to cascade screening
of at risk relatives within known ADPKD families.
Here we aim to identify clinical features from routinely
collected data (primary care records) that could be used in
the early identification of people at high risk of ADPKD.
We use a cross-sectional analysis to assess whether known
clinical features of ADPKD enable the condition to be
distinguished from a large primary care population.
Methods
We performed a cross-sectional analysis on people
included in the Quality Improvement in Chronic Kidney
Disease (QICKD) trial database. The QICKD trial was a
three-arm cluster randomised controlled trial to analyses
the impact of audit-based education on blood pressure
control in people with renal disease [23]. The QICKD trial
database comprises routinely collected data from 127
primary care practices across England. These practices are
a nationally representative sample of urban, sub-urban,
and rural practices in London, Surrey, Sussex, Leicester,
Birmingham, and Cambridge. Anonymised patient records
for all patients registered at these practices were collected
in December 2010 and included all electronic patient
records available up until this date.
England has a registration based primary health care
system. With very few exceptions the whole population
is registered with a single primary care centre. Patients
access non-emergency services through their primary
care practitioner who receives letters about all hospital
attendances including emergencies. Since 2004 there has
been a pay-for-performance system with remuneration
based on extracts from routine data [24]. Primary care
records in the UK therefore provide a comprehensive
patient record.
The QICKD database contains primary care records
extracted during the trial period (January 2006 toDecember 2010). In addition, historical records for each
patient held at their current practice were also available.
We used the data recorded between 2006 and 2010 to
define the characteristics and risk factors of our popula-
tion. All patients registered with their practice at the
time of the final data extraction (December 2010) were
included for analysis (people were excluded if they left
the practice or died before the time of the final data
extraction). The median time of progression to ESRD is
late in the sixth decade of life [5,10]. Our primary focus
here is detection before this stage and we have therefore
limited our analysis to people under 60 years old.
ADPKD case definition
We defined ADPKD cases as anyone who had ever had
one or more clinical code for polycystic kidney disease
entered into their primary care record (Table 1). As
many patients were not categorised by type of polycystic
kidney disease and ADPKD is the most common type all
these cases were included.
Predictor variables
The following variables were hypothesised to be associ-
ated with identified ADPKD: Demographic variables; age
and gender. Clinical variables; systolic blood pressure,
diastolic blood pressure, estimated glomerular filtration
rate (eGFR), serum haemoglobin, haematuria, proteinuria,
the presence of urinary tract infections, and multiple
antihypertensive medications. Age was defined as the
patient’s age in August 2008 (the end of the first round
of data extraction from the trial practices). Patient gender
was available from the patient record.
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records between 01 January 2006 and 31 December
2010. Several blood pressure variables were constructed
to identify the method of analysing blood pressure with
the strongest association with ADPKD. Systolic blood
pressure was defined as the highest recorded blood pres-
sure (recorded during the sample period; 2006 to 2010
inclusive) and the mean systolic blood pressure. Simi-
larly diastolic blood pressure was defined as the highest
diastolic blood pressure and the mean diastolic blood
pressure. These variables were also converted into binary
predictor variables with varying cut-offs e.g. mean systolic
blood pressure over 130 mmHg.
eGFR was calculated from serum creatinine measure-
ments using the mean of two creatinine measurements
where available, if no creatinine measurement was avail-
able lab reported eGFR was used [25]. eGFR was calcu-
lated using the Modification of Diet in Renal Disease
(MDRD) equation [26]. Patients were categorised by CKD
stage or as renal function not measured if no creatinine or
eGFR measurements were available. Serum haemoglobin
was analysed as a continuous variable and as a categorical
variable with four levels; polycythaemia (haemoglobin; Hb
>18.0 g/dl male and >16.0 g/dl female), anaemia (Hb
<13.5 g/dl male and <11.5 g/dl female), normal, and not
measured. The haemoglobin value used was the earliest
recorded during the sample period. Extreme values (less
than 3 g/dl and more than 30 g/dl) were excluded as likely
inputting errors.
Haematuria was defined as the presence of any Read
code pertaining to the detection, history, or observation
of blood in the urine. Proteinuria was defined using a
cascading hierarchy of investigation types which we have
previously described [27]. In brief, the presence of pro-
teinuria was defined using albumin-creatinine ratio
(ACR) where this was measured, if ACR was unavailable
then protein-creatinine ratio (PCR) was used, then 24
urinary protein, then urinalysis (urine dipstick) results
respectively. Individuals were classified as having pro-
teinuria or no proteinuria using previously defined
thresholds [27]. Where no urinary protein test was
recorded the person was classified as not measured. A
urinary tract infection was defined as the presence of
one or more diagnostic Read codes for any urinary tract
infection or laboratory confirmed identification of a pure
culture of pathogenic bacteria from a urine sample.
Multiple antihypertensive medications was defined as
one or more ACEI or angiotensin receptor blocker and
one more calcium channel antagonist or diuretic prescribed
simultaneously.
Statistical methods
A logistic regression model was developed to identify
associations between the predictor variables and thepresence of ADPKD. Model selection was performed
using backwards stepwise elimination of non-significant
variables (p value >0.05). Odds ratios (ORs) with 95%
confidence intervals were calculated for all of the vari-
ables included in the final regression model. The area
under the receiver operating characteristic (AUROC)
curve is reported as a measure of the predictive accuracy
of the model. Additional model validation was carried out
including Hosmer-Lemeshow tests for goodness-of-fit and
collinearity studies. The presence of missing data was
accounted for by including a data not recorded category
for all relevant variables and analysing the effect of miss-
ing data as a predictor for ADPKD.
The risk model was converted into a risk stratification
score. This score could be applied to primary care data-
bases to identify people who have a high likelihood of
having ADPKD and who may be suitable for a future
screening program with renal ultrasound. The scores
assigned to each component were calculated by multiply-
ing the regression coefficients from the logistic regression
model by two and rounding to the nearest integer. The
summation of these scores across all variables gives an
individual risk score for ADPKD. The sensitivity, specifi-
city, positive predictive value (PPV), negative predictive
value (NPV), and proportion of patients with ADPKD
were calculated for each cut-off score.
All statistical analyses were performed using the statis-
tical package R version 2.15.3 (The R Foundation for
Statistical Computing).
Ethical considerations
The original QICKD trial was approved by the Oxford
Research Ethics Committee. Details of the ethical ap-
proval are contained in the trial registration (Current
Controlled Trials reference: ISRCTN56023731. URL:
http://www.controlled-trials.com/ISRCTN56023731). All
data were anonymised at the point of data extraction so
no patient identifiable data were used in this study. Per-
mission for the use of the patient data collected for the
trial for secondary analyses was included in the original
trial ethical approval and additional permissions were
sought to access the trial database. All data use was
compliant with data governance requirements of the
University of Surrey.
Results
Everyone who was included in the QICKD trial database
was included for analysis (n = 951,764). We excluded
people who died or left their primary care practice before
the final data collection in December 2010 (n = 109,701).
As our focus is on early diagnosis of ADPKD we excluded
all adults over 60 years old (n = 157,551). From the
remaining population (N = 684,512) we found 255 people
who had one or more diagnostic code for polycystic
Table 2 Read codes which had been used to record
polycystic kidney disease in 255 identified cases
Read codes:
5-byte version 2
Read codes: version
3 (equivalent)
Number of patients
with code
PD11. PD11. 202
PD111 PD111 109
PD11z X785m/XE1LN 9
Some individuals had more than one clinical code in their medical record.
Other diagnostic codes for polycystic kidney disease not included in this table
were not used by clinicians or were not available in our dataset.
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of PKD in this population of 0.04% or approximately 1
in 2700.
The mean age of people without ADPKD was 31.47
(standard error of the mean; SEM 16.88). The mean
age of people with ADPKD was 41.48 (SEM 12.83).
There were 331,562 (48.5%) females in the group with-
out ADPKD and 137 (53.7%) in the group with ADPKD
(Table 3). Renal impairment, proteinuria, haematuria,
hypertension, urinary tract infections and use of multiple
antihypertensive medications were more prevalent inTable 3 The prevalence of clinical features associated with PK
People with PKD
n (%) mean (S
Female 137 (53.7)
Age 255 (100.0) 41.48 (12
CKD stage
No impairment 97 (38.0)
Stage 3A 26 (10.2)
Stage 3B 17 (6.7)
Stage 4 17 (6.7)
Stage 5 17 (6.7)
Not measured 81 (31.8)
Proteinuria
Negative 87 (34.1)
Positive 126 (49.4)
Not measured 42 (16.5)
Haemoglobin 29 (11.4) 14.1 g/dl
Haematuria 31 (12.2)
Urinary tract infections 26 (10.2)
Mean systolic BP 27 (10.6)* 129.5 mm
Mean diastolic BP 27 (10.6)* 78.7 mm
Highest systolic BP 27 (10.6)* 146.2 mm
Highest diastolic BP 27 (10.6)* 91.5 mm
Diastolic BP over 90 mmHg 17 (6.7)
Diabetes 13 (5.1)
Multiple antihypertensives 53 (20.8)
*Number of people with more than a single BP recording. SEM = standard error of tpeople with ADPKD than people without. Missing data
was more prevalent in the people without ADPKD.
There was a strong correlation between declining renal
function and ADPKD (Table 4). Proteinuria was also
more likely in ADPKD than the general population as
was haematuria, and taking multiple antihypertensive
medications. Diastolic blood pressure was found to have
a stronger association with ADPKD than systolic blood
pressure. As the two variables had a high degree of
collinearity systolic blood pressure was removed from
the model. Using a single cut-off value diastolic blood
pressure of 90 mmHg was found to produce a binary
variable with the strongest association with ADPKD
(smallest p value). The following were not significantly
associated with ADPKD and were therefore removed
from the model; age, gender, serum haemoglobin, and
the presence of urinary tract infections. The AUROC for
the final model (Table 4) was 0.788.
Using the risk scores calculated from the regression
model coefficients (coefficient multiplied by 2 and rounded
to the nearest integer) produced a range to total individual
risk scores ranging from −3 to 10 (Table 5). The possibleD in people with PKD and people without
People without PKD
EM) n (%) mean (SEM)
331,562 (48.5)
.83) 684,257 (100.0) 31.47 (16.88)
149,848 (21.9)
8,608 (1.3)
372 (0.1)
152 (0.0)
222 (0.0)
525,055 (76.7)
186,446 (27.2)
21,735 (3.2)
476,076 (69.6)
(1.2) 41,243 (6.0) 13.8 g/dl (1.6)
22,452 (3.3)
24,123 (3.5)
Hg (15.9) 42,294 (6.2) 124.7 mmHg (14.8)
Hg (9.0) 42,510 (6.2) 77.1 mmHg (9.4)
Hg (26.1) 42,522 (6.2) 132.4 mmHg (18.8)
Hg (16.6) 42,510 (6.2) 82.3 mmHg (11.8)
10,776 (1.6)
15,988 (2.3)
8,911 (1.3)
he mean, PKD = polycystic kidney disease, BP = blood pressure.
Table 4 Associations between clinical features and
polycystic kidney disease in a primary care population of
684,512 people with 255 identified cases of polycystic
kidney disease
Clinical feature Odds Ratio (95%
confidence Interval)
p value Regression
score
Renal function
No impairment detected 0.00 [reference] - 0
Stage 3A 3.95 (2.55 - 6.12) <0.001 3
Stage 3B 42.36 (24.20 - 74.16) <0.001 7
Stage 4 101.27 (55.88 - 183.55) <0.001 9
Stage 5 75.08 (42.26 - 133.39) <0.001 9
Not measured 0.28 (0.21 - 0.38) <0.001 −3
Proteinuria
Negative 0.00 [reference] - 0
Positive 1.59 (1.04 - 2.43) 0.0341 1
Not measured 0.90 (0.68 - 1.20) 0.4899 0
Haematuria present 1.85 (1.24 - 2.78) 0.0029 1
Diastolic BP
over 90 mmHg
2.00 (1.20 - 3.34) 0.0078 1
Diabetes 0.31 (0.17 - 0.57) <0.001 −2
Multiple
antihypertensives
3.83 (2.66 - 5.52) <0.001 3
BP = blood pressure.
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ranging from 70.20% to 2.75% and corresponding specific-
ities ranging from 74.91% to 99.99%.
Discussion
The clinical features which best distinguished people
with a diagnostic code for polycystic kidney disease from
the primary care population were found to be chronic
kidney disease (CKD) stage (3A or worse), proteinuria,
haematuria, diastolic BP greater than 90 mmHg and being
on multiple antihypertensive medications. A regressionTable 5 The predictive values of total regression score cut-off
Regression score PPV (%) NPV (%)
−3 0.00 100.00
−2 0.10 99.99
0 0.11 99.98
1 0.48 99.98
3 0.82 99.97
4 3.82 99.97
7 6.40 99.97
8 7.99 99.97
9 8.33 99.97
10 15.56 99.96
PPV = positive predictive value, NPV = negative predictive value.model using these features was used to create individual
patient risk scores which can be used to predict the likeli-
hood of ADPKD and could be useful as a pre-screening
risk identification tool.Strengths and limitations
This is the first analysis that we are aware of which uses
a non-specialist clinical dataset to perform an analysis of
factors associated with a diagnosis of ADPKD. This has
enabled the comparison of people with ADPKD with the
general population and the identification of factors
which could be used to identify individuals at greater
risk of ADPKD from existing primary care datasets.
The prevalence 1 in 2700 of ADPKD identified here is
lower than previously reported; 1 in 400 to 1000 [2-5].
However these estimates have been based on extrapolations
from small samples. Our prevalence estimate is comparable
to a more recent analysis that used case identification from
the hospital and primary care settings; 1 in 1700 to 3000
[28]. Under-recording of ADPKD in primary care may be a
contributory factor. A second factor is that ADPKD will
have not yet become apparent or have been diagnosed in
the younger people in the studied population. The average
age of the people with diagnosed ADPKD is over 10 years
higher than the average age of the people without ADPKD
strongly suggesting that there is under-diagnosis in the
younger population. Additional family studies to identify at
risk but undiagnosed relatives of all known cases would also
be important for future studies. The impact of these effects
in unclear although it seems likely that the inclusion of
these cases would improve the PPV of the model.
Using routinely collected data has many limitations [29].
These results are reliant on accurate recording of these
data by primary care clinicians and a small amount of
miscoding and misclassification has been previously noted
to occur [30]. However these data are real world data
which is the data available to primary care clinicians ands for polycystic kidney disease
Sensitivity (%) Specificity (%) Detection rate
100.00 0.00 1 in 2,683
70.20 74.91 1 in 959
68.24 76.73 1 in 915
34.90 97.29 1 in 209
30.20 98.63 1 in 121
21.57 99.80 1 in 25
20.00 99.89 1 in 15
14.51 99.94 1 in 12
13.33 99.95 1 in 11
2.75 99.99 1 in 5
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and applicable in primary care.
The nature of a cross-sectional analysis is such that
we were unable to determine whether abnormalities
were coded into the electronic record before or after
the diagnosis of ADPKD. It is likely that there is bias
towards increased renal function testing, BP monitoring,
and antihypertensive use following diagnosis which may
be responsible for some of the associations identified
here. A longitudinal analysis, using a dataset with a longer
duration of follow-up, is required to establish the direction
of causation in these apparent associations.
There were additional clinical features of ADPKD which
we were unable to include in our model as they have not
been collected from primary care records as part of the
original QICKD trial data collection. These comprise; the
presence of abdominal pain, renal colic, and abdominal
masses. These variables may help to improve the predict-
ive capacity of future models. Furthermore family history
of ADPKD is a highly important risk factor which was not
available in our dataset and should be incorporated into
future models. Some of the features of included in our
model such as CKD stages 3B to 5 are already indications
for renal tract ultrasound scanning. This may limit the
utility of this approach to case identification although
other included features do not preclude investigation.
Coding of polycystic kidney disease was not specific
for type of disease. As ADPKD is the most common
form we have assume that all patients coded without
polycystic kidney disease type are ADPKD cases. This
necessarily means that our case definition for ADPKD
will potentially capture a small number of other types of
polycystic kidney disease.
Comparison with the literature
To the best of our knowledge no population based screen-
ing method for ADPKD has yet been devised. Ultrasound
provides a cheap and safe method for diagnosis and
screening of people with high likelihood of ADPKD [31]
but cost will prevent this screening from being applied to
the whole population. Screening selected people with a
high pre-test probability with ultrasound may be a cost
effective way to identify people early on with ADPKD
when effective treatment becomes available.
Implications
These data suggest that development of a targeted
ADPKD screening program is possible. This program
could consist of two stages: Firstly risk stratification in
primary care using routinely collected primary care data
would enable the identification of high risk individuals.
Secondly these people should be referred for ultrasound
scanning or additional screening tests to identify or
exclude ADPKD. Such a screening program is likely toprove cost effective as novel therapies for ADPKD
emerge.
Further research
Application of the models presented here to other large
population datasets is needed to verify our findings.
Additionally longitudinal data would help to ascertain
which of the identified ADPKD predictors are most
commonly measured early in the disease process. This
is the next essential step in development of a tool to
predict people at high risk of ADPKD and would enable
refinement of the population group which should be
sent for screening. Using a combination of a disease
registry for ADPKD (from secondary care data) and pri-
mary care data would facilitate this aim.
Conclusions
Whilst the limitations of the available data prevent us
from conclusively demonstrating that early ADPKD case
finding is possible using routine primary care data, this
approach appears promising. A longitudinal analysis using
linked primary and secondary care data could more
conclusively demonstrate whether or not this method
could be used in ADPKD screening. If this approach
proves successful it could be used to form the basis for or
an adjunct to an ADPKD screening program.
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